Icahn begins his assault on Forest Labs CEO

Once it became apparent that Carl Icahn had accumulated a significant stake in Forest Labs, the analysts sat back waiting for the other shoe to drop. That happened today, as Icahn targeted Forest CEO Howard Solomon for a long litany of abuses: From trouble with the feds to a "poor" record on earnings. Icahn has made a fortune toppling biopharma CEOs at Biogen Idec and Genzyme. And with close to 7 percent of Forest's shares in his portfolio, it appears that the 83-year-old Solomon is now in for the Icahn treatment. Story

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.